Search - tctmd.com

Displaying 1 - 20 of 3214

Sort: Relevancy | Date

Presentation

Triple Antithrombotic Therapy Is the Independent Predictor of Major Bleeding Complications

Presenter: Y. Naruse

August 26, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation GI2 2012

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Presenter: Fausto Feres

April 13, 2012

Presentation

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Presenter: Greg C. Flaker

October 09, 2012

Presentation SOLACI 2016

Adjunctive Pharmacology for Patients with ACS Treated Invasively

Presenter: Eric R. Bates

June 09, 2016

Presentation

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Presenter: C.W. Lee

October 10, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

News Daily News

Aspirin Hypersensitivity Can be Managed in PCI Patients Without Switching Drugs

Todd Neale

January 20, 2016

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

Presentation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presenter: T. Tada

June 01, 2012

Presentation

Stopping vs Continuing Aspirin Before Coronary Artery Surgery

Presenter: Paul Myles

February 24, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Todd Neale

August 28, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

Drug Company Payments to Physicians May Be Influencing Prescribing

Todd Neale

August 23, 2016

Advertisement

Triple Antithrombotic Therapy Is the Independent Predictor of Major Bleeding Complications

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Dual Antiplatelet Therapy Post PCI: Challenging the Guidelines

Bleeding with Aspirin vs. Apixaban in Patients with A-fib Unsuitable for Warfarin: The AVERROES Trial

Adjunctive Pharmacology for Patients with ACS Treated Invasively

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Aspirin Hypersensitivity Can be Managed in PCI Patients Without Switching Drugs

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Stopping vs Continuing Aspirin Before Coronary Artery Surgery

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Drug Company Payments to Physicians May Be Influencing Prescribing

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content